Compelling 90% Success Rate for Remplir in Real World Study
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Orthocell Ltd has announced the results of the Remplir nerve repair study, highlighting a high success rate in nerve repair procedures. The findings support ongoing commercial growth in the U.S. and upcoming European markets, with regulatory approval anticipated in the near future. Orthocell's CEO emphasized the strong clinical outcomes and expanding adoption among surgeons as key factors for the product's success.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Orthocell
- Q3 FY26 Investor Presentation
- First Surgical Use of Remplir in US Department of Defense
- Orthocell Secures Approval to sell Remplir™ to the U.S. Department of Defence Hospital Network
- OCC Secures Access to 221 U.S. Military Medical Centres
- Remplir Used in 23 Surgeries in Ukrainian soldiers
Later from Orthocell
- First Sales of Remplir Achieved in US$75m Canadian Market
- Remplir™: Australian Nerve Repair Device Supports Victims of War in Ukraine
- Orthocell Appoints Thailand Distributor for Remplir
- Q4 FY26 ASX Investor Presentation
- Change of Registered Office & Principal Place of Business
Follow Orthocell into a list and get an email when it puts out news.
Follow Orthocell